Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET

Company Participants

Dave Gancarz - Chief Business and Strategy Officer
Bob Duggan - Chairman of the Board and Chief Executive Officer
Maky Zanganeh - Chief Executive Officer and President
Manmeet Soni - Chief Operating Officer and Chief Financial Officer
Allen Yang - Chief Medical Officer

Conference Call Participants

Bradley Canino - Stifel
Carter Gould - Barclays

Operator

Good morning, ladies and gentlemen, and thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Summit Therapeutics First Quarter 2024 Earnings Conference Call. [Operator Instructions] Also please note that today's call is being recorded.

Thank you. And I would now like to turn the conference over to Mr. Dave Gancarz, Chief Business and Strategy Officer. You may begin.

Dave Gancarz

Thank you. Good morning, and thank you for joining us. Our press release was issued this morning and is available on the homepage of our website. Our Form 10-Q was also filed earlier this morning and is available on our website.

Today's call is being simultaneously webcast, and an archived replay will be available later today on our website, www.smmttx.com.

Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer; Dr. Maky Zanganeh, our Chief Executive Officer and President; Manmeet Soni, our Chief Operating Officer and Chief Financial Officer; and Dr. Allen Yang, our Chief Medical Officer.

Before we get started with the rest of the call, I would like to note that some of the statements made by our management team and some of the responses to questions that we make today may be considered forward-looking statements based on our current expectations. Summit cautions that these forward-looking statements are subject to the risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Please refer to our SEC filings for information about these risks and uncertainties. Summit undertakes no obligation to update these forward-looking statements, except as required by law.

Following comments from Bob, Maky and Manmeet, we will take questions. With that, I would like to turn the call over to Bob.

Bob Duggan

Thank you, Dave. Good morning, everyone, and thank you for joining us today. Before handing the call over to Maky and Manmeet, I'd like to say a few words about our progress and the recent accomplishments of Team Summit. As a reminder, we are enrolling patients in our 2 multiregional registrational Phase III clinical trials, HARMONi and HARMONi-3. Along with our partners at Akeso, we have had ivonescimab data featured multiple medical meetings, including ASCO, American Society of Clinical Oncology; SITC, Society for Immunotherapy of Cancer; and the European Lung Cancer Conference or ELCC as well as the ENA Triple meeting, the annual joint meeting of the European Organization for Research and Treatment of Cancer, the U.S. National Cancer Institute, NCI, and the American Association of Cancer Research, AACR.